Sandy Spring Bank’s Ovid Therapeutics OVID Stock Holding History

Sandy Spring Bank’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$718	Hold	2,300	–	–	﹤0.01%	1114
2024 Q4	$2.15K	Hold	2,300	–	–	﹤0.01%	1062
2024 Q3	$2.71K	Buy	2,300 +300	+15%	+$313	﹤0.01%	1012
2024 Q2	$1.54K	Hold	2,000	–	–	﹤0.01%	1119
2024 Q1	$6.1K	Hold	2,000	–	–	﹤0.01%	935
2023 Q4	$6.44K	Hold	2,000	–	–	﹤0.01%	885
2023 Q3	$7.68K	Hold	2,000	–	–	﹤0.01%	861
2023 Q2	$6.56K	Hold	2,000	–	–	﹤0.01%	914
2023 Q1	$5.16K	Hold	2,000	–	–	﹤0.01%	927
2022 Q4	$3.72K	Hold	2,000	–	–	﹤0.01%	963
2022 Q3	$4K	Hold	2,000	–	–	﹤0.01%	959
2022 Q2	$4K	Hold	2,000	–	–	﹤0.01%	989
2022 Q1	$6K	Hold	2,000	–	–	﹤0.01%	943
2021 Q4	$6K	Hold	2,000	–	–	﹤0.01%	994
2021 Q3	$7K	Buy	+2,000	New	+$7.29K	﹤0.01%	930

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Sandy Spring Bank's OVID Position: Q1 2025 in Review

Sandy Spring Bank held its Ovid Therapeutics (OVID) position steady in Q1 2025 at 2,300 shares worth $718. The position accounts for ﹤0.01% of the portfolio, ranked #1114.

Sandy Spring Bank first reported a position in OVID in Q3 2021 and has held it in 15 quarters since. The position peaked at $7.68K in Q3 2023. 82 funds tracked by Wall St. Rank hold OVID as of Q1 2025.

Sandy Spring Bank held 2,300 shares of Ovid Therapeutics worth $718 as of Q1 2025.
Sandy Spring Bank left its Ovid Therapeutics share count unchanged in Q1 2025.
Ovid Therapeutics made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #1114 holding.
Sandy Spring Bank first reported a position in Ovid Therapeutics in Q3 2021 and has held it in 15 quarters since.
Sandy Spring Bank's Ovid Therapeutics position peaked at $7.68K in Q3 2023.
82 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.